X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
In a post hoc analysis of CABG patients aged 65 years and older treated with 125 units of AGN-151607, a botulinum toxin type A, is a novel investigational neurotoxin the study found a greater risk reduction at 51 percent compared to placebo (nominal p<0.01).
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AGN-151607
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Iran Expo
Not Confirmed
Contact Supplier
Details:
As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axillary hyperhidrosis.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: ET-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eirion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2021
Details:
QM-1114 (botulinum toxin type A) liquid is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for movement disorders such as cervical dystonia.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: QM1114
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
Daewoong Pharmaceutical has added benign masseteric hypertrophy (BMH), commonly known as the square jaw, to the indications for its botulinum toxin (BTX) product, Nabota.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Rare Diseases and Disorders Product Name: Nabota
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Under the termination, Ipsen will retain all rights and obligations related to its early-stage R&D neurotoxin pipeline, including the development of IPN10200 (abobotulinumtoxinA), for the treatment of upper facial lines and muscle spasticity.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: IPN10200
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Galderma
Deal Size: $41.1 million Upfront Cash: $13.7 million
Deal Type: Termination July 27, 2023
Details:
DTX-023 (botulinum toxin type A) is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for primary axillary hyperhidrosis and palmar hyperhidrosis.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: DTX-023
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
Alluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Alluzience
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Medytox applied for a license for Meditoxin (export name: Neuronox having Clostridium Botulinum Toxin type A), Medytox’s BTX product, to China’s National Medical Products Administration in February 2018.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Neurology Product Name: Neuronox
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bloomage Biotechnology Corp., Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination August 04, 2022
Details:
Dysport® is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which has previously shown clinically meaningful benefit in the symptomatic treatment of focal spasticity and cervical dystonia.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Urology Product Name: Dysport
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Strong clinical data supporting Alluzience® (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with a rapid onset and long duration of action of up to six months.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Alluzience
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Alluzience (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation. All currently approved BoNT-A products (or formulations) in Europe come in powder form and require reconstitution with sodium chloride before use.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Alluzience
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Dermatox (DTX-021) is a botulinum toxin type A drug, highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Dermatox
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
One license is for Eirion's neuromodulator-based product candidates, ET-01 and AI-09 for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 and ET-03, which are intended for the treatment of hair loss and hair greying.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: ET-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Haohai Biological Technology
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 09, 2021
Details:
Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks (and at least 16 weeks for pediatric upper limb spasticity).
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Neurology Product Name: Dysport
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Musculoskeletal Product Name: Dysport
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: BoNT/A-DP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2020
Details:
Top-line results showed that 95% of patients treated with Dysport were revealed from severe glabellar lines with two treatments per year, and for 97% the result of the treatment seemed natural.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
